Clinical trial • Phase III • Immunology
SR-878 for Rheumatoid arthritis
Phase III trial of SR-878 for Rheumatoid arthritis. None/Not specified-controlled. 15 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Rheumatoid arthritis
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 30-12-2025
- First CTIS Authorization Date
- 24-04-2026
Trial design
None/Not specified-controlled Phase III trial across 2 sites in Moldova, Republic of, Georgia, Romania.
- Comparator
- None/Not specified
- Target Sample Size
- 15
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 12
Moldova, Republic of
- Number Of Sites
- 0
- Number Of Participants
- 0
Georgia
- Number Of Sites
- 0
- Number Of Participants
- 0
Romania
- Latest Decision Or Authorization Date
- 24-04-2026
- Number Of Sites
- 2
- Number Of Participants
- 12
Sites
- Site Name
- Spitalul Clinic Judetean De Urgenta Cluj
- Department Name
- Ophtalmology building, 1st floor, wards 33, 34, 35
- Contact Person Name
- Daniela Fodor
- Contact Person Email
- Daniela.fodor.ext@arensia-em.com
- Site Name
- Arensia Clinics S.R.L.
- Department Name
- 3rd floor, wards 1, 2, 3, 4, 5, 6 and 7
- Contact Person Name
- Mihai Abobului
- Contact Person Email
- mihai.abobului.ext@arensia-em.com
Sponsor
Primary sponsor
- Full Name
- SciRhom GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- SR-878
Related trials
Other published trials that may interest you.